STUDIEREFERANSER Voluven - Fresenius Kabi

Mai 2009
STUDIEREFERANSER
Voluven ®
MAI 2009

Reviews and Metaanalysis
1. Baron J.F.
A new hydroxyethyl starch: HES 130/0.4, Voluven
Transfusion alternatives in Transfusion medicine, Volume 1, No 2, April 2000
2. Bork K.
Pruritus precipitated by hydroxyethyl starch: a review
Br J Dermatol. 2005 Jan; 152(1):3-12
3. Cheng D, Bélisle S, Giffin M, Karkouti K, Martin J, James M,, Laliberte P, McCluskey S, muihead B, Pendergrast J,
Sharpe M, Waters T
Colloids for perioperative plasma volume expansion: systematic review with meta-analysis of controlled trials
TATM 2007, 9 (Supp 1): S3
4. Davidson IJ
Renal Impact of fluid management with colloids: a compartive review
European Journal of Anaesthesiology, 2006 Sept; 23 (9): 721-38
5. Dieterich H.J.
Recent developments in European colloid solutions
The Journal of Trauma, May supplement 2003; 54, 26 –30
6. James MF.
The role of tetrastarches for volume replacement in the perioperative setting.
Curr Opin Anaesthesiol. 2008 Oct;21(5):674-8. Review.
7. Jungheinrich C
The starch family: are they all equal? Pharmacokinetics and pharmacodynamics of hydroxyethyl starches
TATM 2007, 9: 152-163
8. Jungheinrich C, Neff TA.
Pharmacokinetics of hydroxyethyl starch.
Clin Pharmacokinet. 2005;44(7):681-99.
9. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P.
The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of
randomized clinical trials.
Anesth Analg. 2008 Aug;107(2):382-90.
10. Kozek-Langenecker SA.
Effects of hydroxyethyl starch solutions on hemostasis.
Anesthesiology. 2005 Sep;103(3):654-60.
11. Perner A, Aneman A, Guttormsen AB, Kárason S, Tenhunen J.
Preferences for colloid use in Scandinavian intensive care units. FLUIDS study investigators for the Scandinavian Critical
Care Trials Group.
Acta Anaesthesiol Scand. 2008 Jul;52(6):750-8.
12. Sommermeyer K, Cech F & Schossow R
Differences in chemical structures between waxy maize- and potato starch-based hydroxyethyl starch volume therapeutics
Transfusion Alternatives in Transfusion Medicine 2007 9:127-133
13. Van der Linden P, Ickx BE.
The effects of colloid solutions on hemostasis.
Can J Anaesth. 2006 Jun;53(6 Suppl):S30-9. Review.
14. Wiedermann CJ.
Hydroxyethyl starch--can the safety problems be ignored?
Wien Klin Wochenschr. 2004 Sep 30;116(17-18):583-94. Review.
15. Wiedermann CJ
Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis.
BMC Emerg Med. 2008 Jan 24;8:1.
Pre-Clinical and Animal Trials

16. Bepperling F., Opitz J., Leuschner J.
HES 130/0.4, a new HES specification: Tissue storage after multiple infusions in rats.
Critical Care (1999) Vol.3 Suppl.1 (abstract)
17. Bepperling F., Opitz J., Leuschner J.
Influence of HES 130/0.4 on survival rate in a lethal shock model in rats.
British Journal of Anaesthesia (BJA) Vol. 82 Suppl.1 (1999) (abstract)
18. Fries D, Haas T, Klingler A, Streif W, Klima G, Martini J, Wagner-Berger H, Innerhofer P
Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy--a porcine model.
Br J Anaesth. 2006 Oct;97(4):460-7. Epub 2006 Aug 1.
19. Hoffmann J., Vollmar B., Laschke M., Inthorn D., Schildberg FW
Hydroxyethylstarch (130 kD), but not crystalloid volume support, improves microcirculation during normotensive endotoxemia .
Anaesthesiology 2002, 97:c460-70
20. Johannes T, Egbert GM, Nohe B, Raat NJH, Unertl KE, Ince C.
Influence of fliud resicitation on renal microvascular PO2 in a normotensive rat model of endotoxemia.
Critcal care 2006, 10:R88
21. Leuschner J., Opitz J. Winkler A., Scharpf R. and Bepperling F.
Tissue Storage of 14C-Labelled Hydroxyethyl Starch (HES) 130/0.4 and HES 200/0.5 after Repeated Intravenous Administration
to Rats.
Drugs R&D 2003; 4 (6):331-338.
22. Otsuki DA, Fantoni DT, Margarido CB, Marumo CK, Intelizano T, Pasqualacci CA, Costa Auler Jr JO
Hydroxyethyl starch is superior to lactated Ringer as a replacement fluid in a pig model of acute normovolemic
haemodilution.
Br J Anaesth. 2007, 98(1):29-37
23. Unger J, Haltern C, Kobela JB, Francis R, Rossaint R, Grosse-Siestrup C
Hydroxyethyl starch 130 KD/0.4 and albumin improve CVVH biocompatibility whereas gelatin and hydroxyethyl starch
200KD/0.5 lead to adverse side effects of CVVH in anesthetized pigs
Shock, 2006; 25 (5): 533-545
24. Yang Y
Comparison of 6% hydroxyethyl starch with Ringer's solution on splanchic perfusion in canine with septic shock.
Crit. Care 2006, 10 (Supp 1): P175
Clinical studies with Volunteers
25. Eckle K., Jungheinrich C.,Scharpf R., Wargenau M., Bepperling F.
Pharmacokinetics and Tolerability of a New Hyrdoxyethylstarch Spesification 6% HES 130/0.4 (Voluven) after Single dose
infusion in Subjects with renal impairment.
Anesthesiol Intensiv Med. 200; 41:461 (abstract)
26. Entholzner EK, Mielke LL, Calatzis AN, Feyh J, Hipp R, Hargasser
Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher
molecular weight.
Acta Anaesthesiol Scand 2000 Oct;44(9):1116-21
27. Fries D., Innerhofer P., Klinger A., Berresheim U., Calatzis A.
The effect of combined administration of colloids and Ringer`s Lactate on the coagulation system – an in vitro study using TEG
Critical Care, Vol. 5, Suppl 1, 2001 (abstract)
28. James M.F.M., Latoo M.Y., Mythen M.G., Mutch M., Michaelis Ch., Roche A.M., Burdett E.
Plasma volume changes associated with two hydroxyethyl starch colloids following acute hypovolaemia in volunteers.
Anaesthesia, 59 (2004): 738-742
29. Konrad, C. J., Markl T., Schuepfer G.
In Vitro Effects of Different Medium Molecular Hydroxyethyl Starch Solutions and Lactated Ringer`s Solution on Coagulation
Using Sonoclot.
Anesth. Analg. 90 (2000) 274-9
30. Schroeder, F., Standl, T., Nierhaus, A., Burmester, M.A., Schulte, J.
Tissue oxygenation during acute normovolemic hemodilution with a newly designed hydroxyethyl starch solution in volunteers
Journal of the American Society of Anesthesiologists, 93 (2000) (abstract)
31. Standl, Burmeister, Schroeder, Currlin, Esch, Freitag, Schulte
Hydroxyethyl Starch (HES) 130/0,4 Provides Larger and Faster Increases in Tissue Oxygen Tension in Comparison with
Prehemodilution Values than HES 70/0,5 or HES 200/0,5 in Volunteers Undergoing Acute Normovolemic Hemodilution
Anesth Analg 2003; 96: 963-43
32. Waitzinger, J., Bepperling, F., Pabst, G., Opitz, J., Müller, M., Baron, JF.
Pharmacokinetics and Tolerability of a New Hydroxyethylstarch (HES) Specification (HES 130/0.4) after Single Dose Infusion of
6% or 10% Solution in Healthy Volunteers.
Clin. Drug. Invest. 16 (1998) 151-160

33. Waitzinger, J., Bepperling, F., Pabst, G., Opitz, J., Fackelmayer, A., Boldt, J.
Effect of a New Hydroxyethyl Starch (HES) Specification (6% HES 130/0.4) on Blood and Plasma Volumes after Bleeding in 12
Healthy Male Volunteers.
Clin. Drug. Invest. 17 (2) (1999) 119-125
Cardiac and Aortic Surgery
34. Boldt, J., Lehmann A., Römpert R., Haisch G., Isgro F.
Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass.
J Cardiothorac Vasc Anesth 14 (2000) 264-268
35. Boks RH, Wijers MJ, Hofland J, Takkenberg JJ, Bogers AJ.
Low molecular starch versus gelatin plasma expander during CPB: does it make a difference?
Perfusion. 2007 Sep;22(5):333-7.
36. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, Bepperling F.
“A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery.”
Can J Anaesth 2000 Dec;47(12):1207-15
37. Kasper SM, Meinert P, Kampe S., Görg C, Geisen C., Mehlhorn U., Diefenbach C.
Large dose hydroxyethyl starch (HES) 130/0.4 does not increase Blood loss and transfusion reguirements in coronary artery
bypass surgery compared with Hydroxyethylstarch 200/0.5 at recommended doses.
Anasthesiology V99, No 2, Jul 2003.: 42-47.
38. Morariu AM, Gu YJ, Huet RC, Siemons WA, Rakhorst G, Oeveren WV.
Red blood cell aggregation during cardiopulmonary bypass: a pathogenic cofactor in endothelial cell activation?
Eur J Cardiothorac Surg. 2004 Nov;26(5):939-46
39. Riesmeier A, Schellhaass A, Boldt J, Suttner S.
Crystalloid/colloid versus crystalloid intravascular volume administration before spinal anesthesia in elderly patients: the
influence on cardiac output and stroke volume.
Anesth Analg. 2009 Feb;108(2):650-4
40. Rittoo D, Gosling P, Burnley S, Bonnici C, Millns P, Simms MH, Smith SR, Vohra RK
Randomized study comparing the effects of hydroxyethyl starch solution with Gelofusine on pulmonary function in patients
undergoing abdominal aortic aneurysm surgery.
Br J Anaesth. 2004 Jan;92(1):61-6.
41. Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, Paep RD, Rodrigus I, Daper A, Trenchant A.
Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on
perioperative bleeding and transfusion needs.
Anesth Analg. 2005 Sep;101(3):629-34.
42. Verheij J, van Lingen A, Raijmakers PG, Rijnsburger ER, Veerman DP, Wisselink W, Girbes AR, Groeneveld AB
Effect of fluid loading with saline or colloids on pulmonary permeability, oedema and lung injury score after cardiac and major
vascular surgery.
Br J Anaesth. 2006 Jan;96(1):21-30. Epub 2005 Nov 25.
43. Verheij J, van Lingen A, Beishuizen A, Christiaans H, de Jong J, Girbes A, Wisselink W, Rauwerda J, Huybregts M,
Groeneveld J
Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery
Intensive Care Med, 2006 Jul; 32 (7): 1030-8
44. Yap WW, Young D, Pathi V.
Effects of gelatine and medium molecular weight starch as priming fluid in cardiopulmonary bypass--a randomised controlled
trial.
Perfusion. 2007 Jan;22(1):57-61.
Major abdominal surgery
45. Boldt J., Ducke M., Kumle B., Papsdorf M. And Zurmeyer E.L
Influence of different volume replacement stratgies on inflammation and endothelial activation in the elderly undergoing major
abdominal surgery.
Intensive Care Med (2004) 30: 416-422.
46. Boldt J, Schölhorn T, Mayer J, Piper S, Suttner S
The value of an albumin based intravscular volume replacement strategy in elderly patients undergoing major abdominal
surgery
Anesth. Analg., 2006; 103: 191-9
47. Haisch G., Boldt J., Krebs C., Kumle B., Suttner S., Schulz A.
The influence of intravascular volume therapy with a new hydroxyethyl starch prepartion (6% HES 130/0.4) on coagulation in
patients undergoing major abdominal surgery.
Anesth Analg 2001; 92:565-71
48. Harten J, Crozier JE, McCreath B, Hay A, McMillan DC, McArdle CS, Kinsella J.

Effect of intraoperative fluid optimisation on renal function in patients undergoing emergency abdominal surgery: a randomised
controlled pilot study
Int J Surg. 2008 Jun;6(3):197-204. Epub 2008 Mar 12.
49. Ickx B.E., Bepperling F., Melot C., Schulman C., Van de Linden P.J.
Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended
acute normovolemic haemodilution.
British Journal of Anaesthesia 91 (2): 196-202 (2003)
50. Lang K., Boldt J., Suttner S., Haisch G.
Colloids vs. Crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery
Anesth Analg 2001; 93: 405-9
51. Lang MD, Suttner MD, Boldt PhD
Volume replacement with HES 130/0,4 may reduce the inflammatory response in patients undergoing major abdominal surgery
Can J Anesth 2003 50:10 1009-1016
52. Volta CA, Alvisi V, Campi M, Marangoni E, Alvisi R, Castellazzi M, Fainardi E, Manfrinato MC, Dallocchio F, Bellini T.
Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study.
Anesthesiology. 2007 Jan;106(1):85-91.
Orthopedic surgery
53. Gandhi S, Warltier D, Weiskopf R, Bepperling F, Baus D, Jungheirich C
Volume substitution therapy during major orthopaedic surgery using Voluven (HES 130/0,4) or Hetastarch
Anaesthesiology 2007; 106(6):1120-7
54. Jungheinrich, C, Sauermann, W., Bepperling, F., Vogt, N.H.
Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimized in
vivo molecular weight in orthopedic surgery: a randomized, double-blind study.
Drugs R & D 2004; 5, 1: 1-9
55. Langeron O., Hbitz D., Faure E., Marty J. Coriat P.
Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic
surgery than HES 200/0.5.
Anesth Analg 2001;92:855-62
56. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koepf M, Innerhofer
P.
Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen
administration.
Anesth Analg. 2007 Oct;105(4):905-17
57. Walker R, McCarthy G
Neutrophil elastase suppression by medium-molecular weight hydroxyethylstarch in orthopaedic surgery
Crit. Care 2007, 11 (Supp 2): P407
Urological Surgery
58. Ellger B., Freyhoff J., Vogt M., Van Aken H.
High dose volume replacement using HES 130/0.4 during major surgery does not alter coagulation
European Journal of Anaesthesiology 2002, 10th ESA, Nice (abstract)
Trauma patients
59. Neff T., Jungheinrich C., Doelberg M., Sauerland A., Spahn D., Stocker R.
Repetitive Infusion of the Novel Hydroxyethyl Starch 130/0,4 in Patients with severe Head Injury
Anesth Analg 2003; 96: 1453-9
Stroke patients
60. Grauer MT., Baus D., Woessner R., Bepperling F., Kahles T., Georgi S.
Effects on general safety and coagulation after long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 in
patients with acute ischemic stroke.
Critical Care, Vol 5, Suppl 1, 2001-07-23 (abstract)
61. Rudolf J.
Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled
phase II safety study.
Cerebrovasc Dis 2002; 14:33-41
62. Woessner R, Grauer MT, Dieterich HJ, Bepperling F, Baus D, Kahles T, Georgi S, Bianchi O, Morgenthaler M, Treib J.

Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on
hemodynamics, rheology and hemostasis in patients with acute ischemic stroke. Results of a randomized, placebo-controlled,
double-blind study.
Pathophysiol Haemost Thromb. 2003 May-Jun;33(3):121-6.
Renal function
63. Blasco V, Leone M, Antonini F, Geissler A, Albanèse J, Martin C
Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal
function after transplantation.
British Journal of Anaesthesia feb 2008 100(4):504-508; doi:10.1093/bja/aen001
64. Boldt J, Brosch C, Ducke M, Papsdorf, Lemann A
Influence of volume therapy with a modern hydroxyethylstarch praparation on kidney function in cardiac surgery patients with
compromised renal function: A comparason with human albumin.
Crit Care Med 2007 Vol 35, No.11
65. Boldt, Brenner, Lehmann, Lang, Kumle, Werling
Influence of two different volume replacement regimens on renal function in eldery patients undergoing cardiac surgery:
Comparison of a new starch preparation with gelatin
Intensive care Med 2003, 29: 763-769.
66. Boldt J, Bosch K, Röhm K, Papsdorf M, Mengistu A
Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in
elderly cardiac surgery patients
Br J Anaesth feb 2008, 100(4):457-64
67. Boldt J, Brosch Ch, Röhm K, Lehmann A, Mengistu A, Suttner S.
Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation,
endothelial activation, and long-term kidney function?
Anesth Analg. 2008 Nov;107(5):1496-503.
68. Fenger-Eriksen C, Hartig Rasmussen C, Kappel Jensen T, Anker-Moller E, Heslop J, Frokaer J, Tonnesen E.
Renal effects of hypotensive anaesthesia in combination with acute normovolaemic haemodilution with hydroxyethyl starch
130/0.4 or isotonic saline.
Acta Anaesthesiol Scand. 2005 Aug;49(7):969-74.
69. Godet G, Lehot J,Janvier G, Steib A, De Casto V and Coriat P.
Safety of HES 130/0.4 (Voluven) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a
prospective, randomized, controlled, parallel-group multicentre trial.
Eur J Anaesthesiol. 2008 Dec;25(12):986-94. Epub 2008 May 20. Erratum in: Eur J Anaesthesiol. 2008 Dec;25(12):1042.
70. Jakob SM.
Prevention of acute renal failure--fluid repletion and colloids.
Int J Artif Organs. 2004 Dec;27(12):1043-8.
71. Jungheinrich, Scarph, Wargenau, Bepplinger, Baron
The Pharrmacokintics and Tolerability of an Intravenous Infusuon of the New Hydroxyethyl Starch 130/0,4 in Mild-to-Severe
Renal Impairment
Anesth Analg 2002; 95:544-51
72. Mahmood A, Gosling P, Vohra RK.
Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm
surgery.
Br J Surg. 2007 Apr;94(4):427-33
73. Sakr Y, D.Payen, K.Reinhart, Sipmann FS, Zavala E, Bewlwy J, Marx G, Vincent JL
Effects of hydroxyehtylstarch on renal function in criticall ill patients.
British Journal of Anaesthesia 98(2):216-24 (2007).
74. Schortgen F, Girou E, Deye N, Brochard L; CRYCO Study Group
The risk associated with hyperoncotic colloids in patients with shock.
Intensive Care Med. 2008 Dec;34(12):2157-68. Epub 2008 Aug 7.
75. Unger JK, Haltern C, Dohmen B, Gressner A, Grosse-Siestrup C, Groneberg DA, Rossaint R.
Albumin and hydroxyethyl starch 130 kDa/0.4 improve filter clearance and haemocompatibility in haemo- and plasmafiltrationan
in vitro study.
Nephrol Dial Transplant. 2005 Sep;20(9):1922-31. Epub 2005 May 31.
Paediatric patients
76. Gapay A, Siao S, Merin F, Merin A, Diaz M, Tizon S, Baquilod S, Garra N, Kulkarni H.
HES 130/0,4 in children with severe sepsis: an observational case series.
Trans Alt in Trans Med 2007, 9 (suppl 1), 31-59.
77. Haas T, Preinreich A, Oswald E, Pajk W, Berger J, Kuehbacher G, Innerhofer P.

Effects of albumin 5% and artificial colloids on clot formation in small infants.
Anaesthesia. 2007 Oct;62(10):1000-7.
78. Hanart C, Khalife M, De Villé A, Otte F, De Hert S, Van der Linden P
Perioperative volume replacement in children undergoing cardiac surgery: Albumin versus hydroxyethyl starch
130/0.4.
Crit Care Med. 2009 Dec 26. [Epub ahead of print]
79. Khalife M, Hanart C, De Ville A, De Hert S, Van der Linden P
6% HES 130/0.4 versus 4% albumin for volume replacement in paediatric cardiac surgery: cyanotic congenital disease
European Journal of Anaesthesia 2006, Vol 23 (37): A-300 (abstract)
80. Savvina IA.
Intraoperative Voluven use in paediatric Neurosurgical patients
Poster / oral presentation ESICM 16 th Annual congress Amsterdam, 2003
81. Saudan S, M. Pellegrini, D. Ceroni, A. Kaelin, W. Habre
Hydroxyethyl starch 130/0.4 versus 5% human albumin in children undergoing spinal fusion: safety and efficiency
European Journal of Anaesthesia 2006, Vol 23 (37): A-662 (abstract)
82. Standl T, Lochbuehler H, Galli C, Reich A, Dietrich G, Hagemann H.
HES 130/0.4 (Voluven) or human albumin in children younger than 2 yr undergoing non-cardiac surgery. A prospective,
randomized, open label, multicentre trial.
Eur J Anaesthesiol. 2008 Jun;25(6):437-45. Epub 2008 Mar 13.
83. Sung KC, Kum Suk P, Mi Ja Y and Kyoung Ok K.
Effects of intravascular volume therapy using hydroxyethyl starch (130/0.4) on post-operative bleeding and transfusion
requirements in children undergoing cardiac surgery: a randomized clinical trial.
Acta Anaesthesiol Scand, 40:108-111, 2006
84. Van der Linden P, Khalife C, Hanart C, De Groote F, De Ville A
Fluid management in children undergoing surgery with cardiopulmonary bypass for congenital heart disease: Is albumin still the
best choice?
Transf Alt in Tranf Med 2006, Vol 8 nunb 1: 22-24
Cesarean Section
85. Economou S, Iatreli I, Saridou M, Roubos P, Kadilieraki N, Georgakis T, Chatzikonstandi C, Rali S, Pavlopoulos F
Hemodynamic stability of patients under spinal anesthesia. Comparison of two methods of volume preloading
European Journal of Anaesthesia 2006, Vol 23 (37): A-411 (abstract)
86. Ko JS, Kim CS, Cho HS, Choi DH
A randomized trial of crystalloid versus colloid solution for prevention of hypotension during spinal or low-dose combined
spinal-epidural anesthesia for elective caesarean delivery.
International Journal of obstetric Anesthesia. (2007) 16,8-12 (abstract)
87. Madi-Jebara SN, Ghosn A, Cherfane A, Antakly MC and Yazigi A.
Prevention of hypotension after spinal anesthesia for cesarean section: Voluven (6 % hydroxyethyl starch 130/0.4) versus
lactated ringers solution.
Lebanese Med J 2008; 56(4):203-6
88. Secure MJ, Camino G, Piccolo M and De Nicola A.
Effectiveness of volume preload before spinal anaesthesia for caesarean section: 6% hydroxyethyl starch 130/0.4 vs lactated
ringers solution.
San Leonardo Hospital, Dept. of Anaestesiology, Pompei Italy (abstract)
Septic patients
89. Dieterich HJ
Hydroxyethyl starch and inflammation.
Transf Alt in Tranf Med 2007, 9 (Suppl 1), 1-30.
90. Dieterich HJ, Weissmüller T, Rosenberg P, Eltzschig H
Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia
Crit Care Med, 2006; 34 (6): 1775-82
91. Ertmer C, Rehberg S, Lange M, Bröking K, Morelli A, Van Aken H, Rübig E, vom Roth F, Westpahl M.
Hemodynamic and renal effects of different starch solutions in ovine endotoxemia
Poster / oral presentation ESICM 20 th Annual congress Berlin, 2007
92. Galstyan GM, Serebriysky II, Berkovsky AL, Vasiliew SA, Rudakova VE, Sergeeva EV, Gorodetsky VM
Influence of hydroxyethyl starch (HES) on Hemostasis in patients (PTS) with sepsis
Intensive Care Medicine, 2006: 32 (Suppl 1): S0692
93. Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M
Resuscitation from septic shock with capillary leakage: hydroxyethyl starch (130 kd), but not Ringer's solution maintains plasma
volume and systemic oxygenation.
Shock. 2004 Apr;21(4):336-41.

94. Meyer P, Permet I, Hejblum G, Baudel J, Maury E, Offenstadt G, Guidet B
Haemodilution induced by hydroxyethyl starches 130/0.4 is similar in septic and non-septic patients.
Acta Anaesthesiol Scand. 2008 Feb;52(2):229-35. Epub 2007 Nov 22.
95. Palumbo D, Servillo G, D'Amato L, Volpe ML, Capogrosso G, De Robertis E, Piazza O, Tufano R
The effects of hydroxyethyl starch solution in critically ill patients
Minerva Anestesiol, 2006; 72: 655-64
96. Turani, Rosati, Redi, Leonardis, Celeste, Colella, Curatola
Cardiac and volumetric response to two different colloids in septic patients
Poster / oral presentation ESICM 16 th Annual congress Amsterdam, 2003
Coagulation
97. Ahn HJ, Yang M, Gwak MS, Koo MS, Bang SR, Kim GS, Lee SK.
Coagulation and biochemical effects of balanced salt-based high molecular weight vs saline-based low molecular weight
hydroxyethyl starch solutions during the anhepatic period of liver transplantation.
Anaesthesia. 2008 Mar;63(3):235-42.
98. Boldt J, Suttner S, Brosch C, Lehmann A, Mengistu A.
Influence on coagulation of a potato-derived hydroxethylstarch (HES 130/0.42) and a maize-derived hydroxethylstarch (HES
130/0.4) in patients undergoing cardiac surgery.
Br J Anaesth. 2009 Feb;102(2):191-7. Epub 2008 Dec 10.
99. Boldt J, Mengistu A, Seyfert UT, Hellstern P.
The impact of a medium molecular weight, low molar substiution hydroxyethyl starch dissolved in a physiologically balanced
electrolyte solution on blood coagulation and platlet function in vitro.
Vox Sanguinis (2007) 93, 139-144
100. Boldt J, Wolf M, Mengistu A
A new plasma-adapted Hydroxyethylstarch praparation: In vitro coagulation studies using thrombelastography and whole blood
aggregometry
Anesthesia Ann. Vol 104, No2, feb, 2007: 425-430
101. Boldt J, Haisch G, Sutter S, Kumle B, Scellhaass A
Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation
Brit Jour of Anaesth 2002, 89 (5): 722-8
102. Bulanov A, Sulutko E, Scherbakova O, Lubimova L, Gelnova E, Sudeikina N.
Effects of different colloid solutions on clot formation in healty donors.
Trans Alt in Trans Med 2007, 9 (suppl 1), 31-59.
103. Chen G, Yan M, Lu Q, Gong M
Effects of two different hydroxyethyl starch solutions (HES 200/0,5 vs. HES 130/0,4) on the expression of platelet
membrane glycoprotein.
Acta Anaesthesiol Scand. 2006, 50: 1089-1094
104. Ellger, Freyholdt, Vogt, Aken, Marcus, Booke
High-dose volume replacement using HES 130/0,4 during major surgery. Impact on coagulation and incidence of postoperative
iching.
Ned Tids voor Anesth, 2006 vol 19: 63-68
105. Felfernig, Franz, Braunlich, Fohringer, Kozek-Langenecker
The effects of hydroxyethyl starch solutions on thromboelastography in preoperative male patients
Acta Anaesthesiologica Scandinavia 2003: 47: 70-73
106. Fenger-Eriksen C, Anker-Moller E, Heslop J, Ingerslev J, Sorensen B
Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced
coagulopathy with fibrinogen concentrate.
Br J Anaesth. 2005 Mar;94(3):324-9. Epub 2004 Dec 17.
107. Franz, A., Braeunlich, P., Foringer C., Kozek A.
The effects of hydroxyethyl starches of varying molecular weights on platelet function.
Anesth Analg 2001, 92:1402-7
108. Gandhe U, Shetty V, Pande K, Kulkarni S, Kulkarni H
Volume requirement, coagulation profile and outcome parameter comparison of gelatin versus hydroxyethyl starch in coronary
artery bypass graft
Transfusion Alternatives in Transfusion Medicine 2006, 8 (Supp 1): P63 (abstract)
109. Kang JG, Ahn HJ, Kim GS, Hahm TS, Lee JJ, Gwak MS, Choi SJ.
The hemostatic profiles of patients with Type O and non-O blood after acute normovolemic hemodilution with 6% hydroxyethyl
starch (130/0.4).
Anesth Analg. 2006 Dec;103(6):1543-8.

110. Niemi TT, Kuitunen AH.
Artificial colloids impair haemostasis. An in vitro study using thromboelastometry coagulation analysis.
Acta Anaesthesiol Scand. 2005 Mar;49(3):373-8.
111. Scharbert G., Deusch E., Kress H.G., Greher M., Gustorff B., Kozek-Langenecker S.A.
Inhibation of platelet function by hydroxyethyl starch solutions in cronic pain patients undergoing peridural anesthesia..
Anesth Analg 2004; 99: 823-7
112. Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, Kukkonen SI, Niemi TT.
Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial.
Anesth Analg. 2009 Jan;108(1):30-6.
113. von Roten I, Madjdpour C, Frascarolo P, Burmeister MA, Fisch A, Schramm S, Bombeli T, Spahn DR.
Molar substitution and C2/C6 ratio of hydroxyethyl starch: influence on blood coagulation.
Br J Anaesth. 2006 Apr;96(4):455-63. Epub 2006 Feb 7.
Liver transplantation
114. Costa M., Ponpei L., Della Rocca G.
Blood substitution consumption and coagulation changes: 200/0.5 vs. HES 130/0.4 hydroxyethyl starch administration
Critical Care, Vol. 7, suppl. 2, March 2003, (abstract)
115. Pereira L, Oliveira D, Cipriano MA, Neves S, Viana JS
Hydroxyethylstarch 130/0.4 in liver transplantation - evaluation of the effects on graft function and post-operative course
European Journal of Anaesthesia 2006, Vol 23 (37): A-299 (abstract)
Other studies of interest
116. Base E, Standl T, Mahl C, Jungheinrich C.
Comparison of 6% HES 130/0.4 in a balanced electrolyte solution versus 6% HES 130/0.4 in normal saline solution in
cardiac surgery.
Crit. Care 2006, 10 (Supp 1): P176
117. Boldt J., Suttner S., Hüttner I., Kumle B., Piper S., Krumholz W.
Are cost of a crystalloid-based volume replacement regimen lower than of a colloid-based volume replacement
strategy?
Infus Ther Transfus Med 2001;28:144-149
118. Brandstrup B,Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin
L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum
D, Christensen AM, Graungaard B, Pott F.
Effects of intravenous fluid restriction on postoperative complications: comparison of
two perioperative fluid regimens: a randomized assessor-blinded multicenter trial.
Ann Surg 2003; 238: 641-648
119. Habler O, Schwenzer K, Zimmer K, Prager M, Konig U, Oppenrieder K, Pape A, Steinkraus E, Reither A, Buchrot A,
Zwissler B.
Effects of standardized acute normovolemic hemodilution on intraoperative allogeneic blood transfusion in patients undergoing
major maxillofacial surgery.
Int J Oral Maxillofac Surg. 2004 Jul;33(5):467-75.
120. Kasper, SM., Strömich, A., Kampe S, Radbruch L.
Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients
undergoing preoperative autologous blood donation
J Clin Anesth 2001 Nov;13(7):486-90
121. Kim DH, Beez M, Kulkarni H.
Comparative Hemodynamic Evaluation on Hydroxyethylstarch (HES 130/0,4) and Albumin in High Risk Surgical Patients
Transfusion Alternatives in Transfusion Medicine 2005; 7 (1): 79. Poster presented at NATA 2005
122. Klemm E, Bepperling F, Burschka MA, Mösges R; Study Group.
Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: a
dose-finding, double-blind, placebo-controlled, international multicenter trial with 210 patients.
Otol Neurotol. 2007 Feb;28(2):157-70.
123. Neff TA, Fischler L, Mark M, Stocker R, Reinhart WH.
The influence of two different hydroxyethyl starch solutions (6% HES 130/0.4 and 200/0.5) on blood viscosity.
Anesth Analg. 2005 Jun;100(6):1773-80.
124. Schnuelle P, Johannes van der Woude F.
Perioperative fluid management in renal transplantation: a narrative review of the literature.
Transpl Int. 2006 Dec;19(12):947-59

Voluven “Fresenius Kabi”
Kolloidosmotisk oppløsning ATC-nr.:B05A A07
INFUSJONSVÆSKE, oppløsning 60 mg/ml: 1000 ml inneh.: Poly(O-2-hydroksyetyl)stivelse (HES 130/0,4) 60
g, natriumklorid 9 g, saltsyre, natriumhydroksid, vann til injeksjon til 1000 ml. Elektrolyttinnh.: Na+ 154 mmol,
Cl- 154 mmol. pH 4-5,5. Osmolaritet: 308 mosmol/liter. Titrerbar aciditet:

Dosering: Til kontinuerlig i.v. infusjon. De første 10-20 ml infunderes langsomt. I denne perioden må
pasienten observeres nøye pga. faren for anafylaktoide reaksjoner. Dagsdose og infusjonshastighet
bestemmes av pasientens blodtap, den hemodynamiske status og hemodilusjonseffekten. Maks. daglig dose
er 50 ml/kg kroppsvekt/døgn. Voluven kan administreres gjentatte ganger over flere dager i henhold til
pasientens behov. Behandlingens varighet avhenger av hypovolemiens grad og varighet, den
hemodynamiske status og hemodilusjonen. Erfaring med bruk av maks. daglig dose gitt over lengre perioder
er begrenset. Barn: Begrensede kliniske data er tilgjengelig. En gjennomsnittsdose tilsvarende 16 ± 9 ml/kg
kroppsvekt er trygt og vel tolerert av 41 barn, inkl. nyfødte og spedbarn (

For mer informasjon
Kontakt Produktsjef
Jørgen Sørensen på
22 58 80 00 el. 917 61 912
jorgen.sorensen@fresenius-kabi.com